Poster 106 - Once-Daily Valbenazine Improves the Impacts of Tardive Dyskinesia (TD) in Patients From KINECT-PRO™ Who Met a Threshold for TD Remission
Tuesday, April 28, 2026
1:15 PM - 1:45 PM MDT
Location: Screen 13, Exhibit Hall Poster Pavilion
KINECT-PRO™ is the first clinical trial to specifically assess and report the effects of a VMAT2 inhibitor (valbenazine) on the impacts of TD using multiple validated patient-reported outcomes (PROs). This post-hoc analysis evaluated PROs in participants who met a threshold for TD remission at Week 24, defined as a score ≤1 in each of the 7 body region items of the Abnormal Involuntary Movement Scale. In these participants, robust PRO improvements were observed at Week 24.
Learning Objectives:
To understand how a published threshold for remission can be applied to patients with tardive dyskinesia (TD)
To become familiar with the effects of once-daily valbenazine on several validated, patient-reported, quality-of-life measures in patients with TD who met this threshold for TD remission
To recognize the benefits of administering patient-reported outcomes alongside clinician-reported outcomes in clinical studies of tardive dyskinesia
